Chinese medicine composition for treating immune glomerulonephritis

Abstract

This invention discloses a traditional Chinese medicine composition for treating immune glomerulonephritis, belonging to the field of traditional Chinese medicine technology. This invention, through the rational combination of multiple traditional Chinese medicines, targets the symptoms of positive urine protein and positive urine occult blood caused by immune glomerulonephritis. It can effectively reduce urine protein leakage, eliminate urine occult blood, stabilize kidney indicators, and improve kidney immune damage. The medicine is mild in nature, suitable for long-term use, with stable efficacy, low recurrence rate, and no obvious adverse reactions. It is suitable for long-term conditioning and treatment of patients with chronic nephritis. The following raw materials are included in the following weight proportions: 20-30 parts raw Astragalus membranaceus, 12-18 parts wine-processed Cornus officinalis, 15-22 parts processed Polygonatum sibiricum, 10-18 parts Dioscorea nipponica, 18-28 parts Smilax glabra, 12-20 parts Rosa laevigata, 15-22 parts stir-fried Euryale ferox, 3-6 parts Panax notoginseng powder, 12-20 parts Pyrrosia lingua, 10-16 parts stir-fried Atractylodes macrocephala, 6-10 parts processed Glycyrrhiza uralensis, and 20-30 parts Tripterygium wilfordii glycosides.

Description

Technical Field

[0001] A traditional Chinese medicine composition for treating immune glomerulonephritis. Background Technology

[0002] Immune glomerulonephritis is a common chronic kidney disease in clinical practice. Its pathogenesis is closely related to immune dysregulation and damage to the renal mesangium and basement membrane. Typical clinical manifestations include persistent proteinuria and recurrent positive hematuria. The disease is protracted and recurrent, and long-term progression can lead to continuous kidney damage. Current conventional clinical treatments often suffer from recurring symptoms, easy relapse upon discontinuation of medication, and poor long-term tolerance. Conventional symptomatic treatment can only control indicators in the short term and cannot effectively improve the condition in the long term from the perspective of immune regulation and repair of kidney damage, resulting in a large number of patients experiencing recurrent proteinuria and hematuria for many years, making it difficult to cure. Summary of the Invention

[0003] Purpose of the invention: In view of the deficiencies of the existing technology, the present invention provides a traditional Chinese medicine composition that is rationally formulated, has a definite curative effect, is suitable for long-term use, and is specifically designed to improve proteinuria and hematuria in nephritis.

[0004] This invention aims to provide a traditional Chinese medicine composition for treating immune glomerulonephritis, which effectively improves proteinuria and abnormal hematuria caused by nephritis, with a high rate of negative conversion of indicators, strong stability, and low relapse rate, making it suitable for long-term conservative treatment of chronic nephritis.

[0005] Beneficial effects: The composition of this invention can significantly reduce urinary protein leakage in patients with immune nephritis, greatly improve the urinary protein conversion rate, and reduce the loss of renal microorganisms; the composition of this invention has a clear elimination and improvement effect on abnormal occult blood in urine and renal hematuria in nephritis, and has significant hemostatic and hemostatic effects; the formulation is mild and has no strong drug stimulation, making it suitable for long-term use in chronic nephritis, with extremely strong long-term stability and a relapse rate far lower than conventional treatment regimens; the formulation is rigorous and targeted, specifically targeting the two core abnormal indicators (protein and occult blood) of nephritis, with strong therapeutic targeting, significant clinical efficacy, and technical advantages and clinical promotion value superior to existing conventional treatments. Specific Implementation

[0006] Example 1: A traditional Chinese medicine composition for treating immune glomerulonephritis, made from the following raw materials in parts by weight: 20-30 parts of raw Astragalus membranaceus, 12-18 parts of processed Cornus officinalis, 15-22 parts of processed Polygonatum sibiricum, 10-18 parts of Dioscorea nipponica, 18-28 parts of Smilax glabra, 12-20 parts of Rosa laevigata, 15-22 parts of stir-fried Euryale ferox, 3-6 parts of Panax notoginseng powder, 12-20 parts of Pyrrosia lingua, 10-16 parts of stir-fried Atractylodes macrocephala, 6-10 parts of processed Glycyrrhiza uralensis, and 20-30 parts of Tripterygium wilfordii polyglycosides. Pharmacological compatibility description: Astragalus membranaceus + stir-fried Atractylodes macrocephala: strengthens the spleen and replenishes qi, protects kidney qi; Cornus officinalis (processed) + processed Polygonatum sibiricum: tonifies the kidney and replenishes essence, replacing the yin-nourishing and kidney-tonifying effects of Erzhi Wan; Dioscorea nipponica + Panax notoginseng: invigorates blood circulation and unblocks collaterals, improves glomerular microcirculation, replacing Salvia miltiorrhiza; Smilax glabra + Pyrrosia lingua: clears dampness and turbidity in the lower jiao, eliminates turbidity, and reduces the stimulation of damp heat on the kidneys; Rosa laevigata + stir-fried Euryale ferox: consolidates essence and reduces proteinuria; Glycyrrhiza uralensis (processed) harmonizes all the herbs, suitable for long-term use. The entire formula closely addresses the core pathogenesis of nephritis: immune damage, protein leakage, blood heat and hematuria, specifically targeting the two core indicators of proteinuria and hematuria. It has a liver-protective effect. This formula can be made into pills, capsules, or tablets.

[0007] Data from comparative efficacy trials.

[0008] Experimental Groups Sixty patients diagnosed with immune glomerulonephritis, persistent proteinuria (+ to +++), and hematuria (+ to +++) were randomly divided into an observation group (the herbal medicine group of this invention) of 30 patients and a control group of 30 patients. There were no statistically significant differences in the course of the disease and the severity of the indicators between the two groups, making them comparable.

[0009] control group The patient was treated with standard clinical symptomatic treatment for nephritis, without taking the herbal composition of this invention.

[0010] Observation group Under the premise of routine basic care, continue to take the traditional Chinese medicine composition of this invention, one dose per day, for three consecutive months.

[0011] Observation indicators (only two: urine protein, urine occult blood) 1. Negative conversion and improvement of urine protein 2. Negative conversion and improvement of occult blood in urine Experimental results data 1. Results of improvement in urinary protein Control group: 30 cases - Protein turned negative: 4 cases - Significantly reduced protein levels: 9 cases - No improvement, fluctuating symptoms: 17 cases - Overall protein efficacy: 43.3% Observation group: 30 cases (formula of this invention): - Protein turned negative: 13 cases - Significantly reduced protein levels: 14 cases - No significant improvement: 3 cases - Overall protein efficacy: 90.0% 2. Improvement results in occult blood in urine Control group: 30 cases - Negative occult blood test: 5 cases - Significantly reduced occult blood: 10 cases - No improvement despite repeated attempts: 15 cases - Overall effectiveness rate for occult blood: 50.0% Observation group: 30 cases (formula of this invention): - Negative occult blood test: 14 cases - Significantly reduced occult blood: 13 cases - No significant improvement: 3 cases - Overall effectiveness rate for occult blood: 90.0% Long-term stability observation (follow-up 1 month after drug discontinuation) Control group: 19 cases showed relapse or rebound of indicators, with a relapse rate of 63.3%. Observation group: Only 4 cases showed slight fluctuations in indicators without significant rebound, with a recurrence rate of 13.3%.

Claims

1. A traditional Chinese medicine composition for treating immune glomerulonephritis, characterized in that, The following ingredients are included in the following proportions by weight: 20-30 parts raw Astragalus membranaceus, 12-18 parts wine-processed Cornus officinalis, 15-22 parts processed Polygonatum sibiricum, 10-18 parts Dioscorea nipponica, 18-28 parts Smilax glabra, 12-20 parts Rosa laevigata, 15-22 parts stir-fried Euryale ferox, 3-6 parts Panax notoginseng powder, 12-20 parts Pyrrosia lingua, 10-16 parts stir-fried Atractylodes macrocephala, 6-10 parts processed Glycyrrhiza uralensis, and 20-30 parts Tripterygium wilfordii polyglycosides.